LOG IN
SIGN UP
MARKET
ACHV
ACHV
Achieve Life Sciences Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
4.920
+0.010
+0.20%
Opening 14:01 07/05 EDT
OPEN
4.810
PREV CLOSE
4.910
HIGH
4.980
LOW
4.810
VOLUME
5.54K
TURNOVER
14.64K
52 WEEK HIGH
10.09
52 WEEK LOW
4.810
MARKET CAP
47.63M
P/E (TTM)
-1.2967
1D
5D
1M
3M
1Y
5Y
Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation
Achieve Life Sciences (NASDAQ:ACHV) <a href="https://...
Seekingalpha · 6d ago
Achieve Life Sciences Announces Initiation Of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline For Nicotine e-cigarette Cessation
Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it
Benzinga · 6d ago
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and ...
GlobeNewswire · 6d ago
Achieve Life Sciences Begins Phase 2 Trial of Cytisinicline for Nicotine E-cigarette Cessation
MT Newswires · 6d ago
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 329 companies hit new 52-week lows.
Benzinga · 06/22 16:30
Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference
SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessa...
GlobeNewswire · 06/21 12:00
BRIEF-Achieve Life Sciences Awarded Grant To Conduct Phase 2 Trial Of Cytisinicline In Nicotine E-Cigarette Users
reuters.com · 06/01 12:22
Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users
Company awarded $2.5 million to enable initiation of the Phase 2 ORCA-V1 clinical trialSEATTLE and VANCOUVER, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company commi...
GlobeNewswire · 06/01 12:00
No Data
Learn about the latest financial forecast of ACHV. Analyze the recent business situations of Achieve Life Sciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 7 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
28.57%Strong Buy
71.43%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACHV stock price target is 31.75 with a high estimate of 71.00 and a low estimate of 20.00.
Current 4.920
EPS
Actual
Estimate
-1.22-0.92-0.61-0.31
Institutional Holdings
Institutions: 48
Institutional Holdings: 2.59M
% Owned: 26.77%
Shares Outstanding: 9.68M
TypeInstitutionsShares
Increased
7
37.26K
New
6
81.36K
Decreased
8
85.82K
Sold Out
2
19.29K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.40%
Pharmaceuticals & Medical Research
-0.74%
Key Executives
Chairman/Executive Director
Richard Stewart
President/Director
Cindy Jacobs
Chief Executive Officer/Director
John Bencich
Chief Accounting Officer
Jerry Wan
Chief Scientific Officer
Anthony Clarke
Lead Director/Independent Director
Donald Joseph
Independent Director
Vaughn Himes
Independent Director
Bridget Martell
Independent Director
Martin Mattingly
Independent Director
Jay Moyes
No Data
No Data
About ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The Company is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).
Webull offers kinds of Achieve Life Sciences Inc stock information, including NASDAQ:ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.